Differential benefit of statin in secondary prevention of acute myocardial infarction according to the level of triglyceride and high density lipoprotein cholesterol

Korea Acute Myocardial Infarction Registry Investigators

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background and Objectives: The differential benefit of statin according to the state of dyslipidemia has been sparsely investigated. We sought to address the efficacy of statin in secondary prevention of myocardial infarction (MI) according to the level of triglyceride and high density lipoprotein cholesterol (HDL-C) on admission. Subjects and Methods: Acute MI patients (24653) were enrolled and the total patients were divided according to level of triglyceride and HDL-C on admission: group A (HDL-C≥40 mg/dL and triglyceride<150 mg/dL; n=11819), group B (HDL-C≥40 mg/dL and triglyceride≥150 mg/dL; n=3329), group C (HDL-C<40 mg/dL and triglyceride<150 mg/dL; n=6062), and group D (HDL-C<40 mg/dL & triglyceride≥150 mg/dL; n=3443). We evaluated the differential efficacy of statin according to the presence or absence of component of dyslipidemia. The primary end points were major adverse cardiac events (MACE) for 2 years. Results: Statin therapy significantly reduced the risk of MACE in group A (hazard ratio =0.676; 95% confidence interval: 0.582-0.785; p<0.001). However, the efficacy of statin was not prominent in groups B, C, or D. In a propensity-matched population, the result was similar. In particular, the benefit of statin in group A was different compared with group D (interaction p=0.042) Conclusion: The benefit of statin in patients with MI was different according to the presence or absence of dyslipidemia. In particular, because of the insufficient benefit of statin in patients with MI and dyslipidemia, a different lipid-lowering strategy is necessary in these patients.

Original languageEnglish
Pages (from-to)324-334
Number of pages11
JournalKorean Circulation Journal
Volume46
Issue number3
DOIs
Publication statusPublished - 2016 May

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Secondary Prevention
HDL Cholesterol
Triglycerides
Myocardial Infarction
Dyslipidemias
Confidence Intervals
Lipids

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{bd44b78e9d884952967acf2816374372,
title = "Differential benefit of statin in secondary prevention of acute myocardial infarction according to the level of triglyceride and high density lipoprotein cholesterol",
abstract = "Background and Objectives: The differential benefit of statin according to the state of dyslipidemia has been sparsely investigated. We sought to address the efficacy of statin in secondary prevention of myocardial infarction (MI) according to the level of triglyceride and high density lipoprotein cholesterol (HDL-C) on admission. Subjects and Methods: Acute MI patients (24653) were enrolled and the total patients were divided according to level of triglyceride and HDL-C on admission: group A (HDL-C≥40 mg/dL and triglyceride<150 mg/dL; n=11819), group B (HDL-C≥40 mg/dL and triglyceride≥150 mg/dL; n=3329), group C (HDL-C<40 mg/dL and triglyceride<150 mg/dL; n=6062), and group D (HDL-C<40 mg/dL & triglyceride≥150 mg/dL; n=3443). We evaluated the differential efficacy of statin according to the presence or absence of component of dyslipidemia. The primary end points were major adverse cardiac events (MACE) for 2 years. Results: Statin therapy significantly reduced the risk of MACE in group A (hazard ratio =0.676; 95{\%} confidence interval: 0.582-0.785; p<0.001). However, the efficacy of statin was not prominent in groups B, C, or D. In a propensity-matched population, the result was similar. In particular, the benefit of statin in group A was different compared with group D (interaction p=0.042) Conclusion: The benefit of statin in patients with MI was different according to the presence or absence of dyslipidemia. In particular, because of the insufficient benefit of statin in patients with MI and dyslipidemia, a different lipid-lowering strategy is necessary in these patients.",
author = "{Korea Acute Myocardial Infarction Registry Investigators} and Kim, {Kyung Hwan} and Kim, {Cheol Hwan} and Jeong, {Myung Ho} and Youngkeun Ahn and Kim, {Young Jo} and Cho, {Myeong Chan} and Wan Kim and Kim, {Jong Jin} and Ahn, {Young Keun} and Chae, {Shung Chull} and Kim, {Jong Hyun} and Hur, {Seung Ho} and Seong, {In Whan} and Choi, {Dong Hoon} and Chae, {Jei Keon} and Hong, {Taek Jong} and Rhew, {Jae Young} and Kim, {Doo Il} and Chae, {In Ho} and Yoon, {Jung Han} and Koo, {Bon Kwon} and Kim, {Byung Ok} and Lee, {Myoung Yong} and Kim, {Kee Sik} and Hwang, {Jin Yong} and Oh, {Seok Kyu} and Lee, {Nae Hee} and Jeong, {Kyoung Tae} and Tahk, {Seung Jea} and Bae, {Jang Ho} and Rha, {Seung Woon} and Park, {Keum Soo} and Kim, {Chong Jin} and Han, {Kyoo Rok} and Ahn, {Tae Hoon} and Kim, {Moo Hyun} and Seung, {Ki Bae} and Chung, {Wook Sung} and Yang, {Ju Young} and Rhim, {Chong Yun} and Gwon, {Hyeon Cheol} and Park, {Seong Wook} and Koh, {Young Youp} and Joo, {Seung Jae} and Kim, {Soo Joong} and Jin, {Dong Kyu} and Cho, {Jin Man} and Jang, {Yang Soo} and Cho, {Jeong Gwan} and Park, {Seung Jung}",
year = "2016",
month = "5",
doi = "10.4070/kcj.2016.46.3.324",
language = "English",
volume = "46",
pages = "324--334",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "3",

}

Differential benefit of statin in secondary prevention of acute myocardial infarction according to the level of triglyceride and high density lipoprotein cholesterol. / Korea Acute Myocardial Infarction Registry Investigators.

In: Korean Circulation Journal, Vol. 46, No. 3, 05.2016, p. 324-334.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential benefit of statin in secondary prevention of acute myocardial infarction according to the level of triglyceride and high density lipoprotein cholesterol

AU - Korea Acute Myocardial Infarction Registry Investigators

AU - Kim, Kyung Hwan

AU - Kim, Cheol Hwan

AU - Jeong, Myung Ho

AU - Ahn, Youngkeun

AU - Kim, Young Jo

AU - Cho, Myeong Chan

AU - Kim, Wan

AU - Kim, Jong Jin

AU - Ahn, Young Keun

AU - Chae, Shung Chull

AU - Kim, Jong Hyun

AU - Hur, Seung Ho

AU - Seong, In Whan

AU - Choi, Dong Hoon

AU - Chae, Jei Keon

AU - Hong, Taek Jong

AU - Rhew, Jae Young

AU - Kim, Doo Il

AU - Chae, In Ho

AU - Yoon, Jung Han

AU - Koo, Bon Kwon

AU - Kim, Byung Ok

AU - Lee, Myoung Yong

AU - Kim, Kee Sik

AU - Hwang, Jin Yong

AU - Oh, Seok Kyu

AU - Lee, Nae Hee

AU - Jeong, Kyoung Tae

AU - Tahk, Seung Jea

AU - Bae, Jang Ho

AU - Rha, Seung Woon

AU - Park, Keum Soo

AU - Kim, Chong Jin

AU - Han, Kyoo Rok

AU - Ahn, Tae Hoon

AU - Kim, Moo Hyun

AU - Seung, Ki Bae

AU - Chung, Wook Sung

AU - Yang, Ju Young

AU - Rhim, Chong Yun

AU - Gwon, Hyeon Cheol

AU - Park, Seong Wook

AU - Koh, Young Youp

AU - Joo, Seung Jae

AU - Kim, Soo Joong

AU - Jin, Dong Kyu

AU - Cho, Jin Man

AU - Jang, Yang Soo

AU - Cho, Jeong Gwan

AU - Park, Seung Jung

PY - 2016/5

Y1 - 2016/5

N2 - Background and Objectives: The differential benefit of statin according to the state of dyslipidemia has been sparsely investigated. We sought to address the efficacy of statin in secondary prevention of myocardial infarction (MI) according to the level of triglyceride and high density lipoprotein cholesterol (HDL-C) on admission. Subjects and Methods: Acute MI patients (24653) were enrolled and the total patients were divided according to level of triglyceride and HDL-C on admission: group A (HDL-C≥40 mg/dL and triglyceride<150 mg/dL; n=11819), group B (HDL-C≥40 mg/dL and triglyceride≥150 mg/dL; n=3329), group C (HDL-C<40 mg/dL and triglyceride<150 mg/dL; n=6062), and group D (HDL-C<40 mg/dL & triglyceride≥150 mg/dL; n=3443). We evaluated the differential efficacy of statin according to the presence or absence of component of dyslipidemia. The primary end points were major adverse cardiac events (MACE) for 2 years. Results: Statin therapy significantly reduced the risk of MACE in group A (hazard ratio =0.676; 95% confidence interval: 0.582-0.785; p<0.001). However, the efficacy of statin was not prominent in groups B, C, or D. In a propensity-matched population, the result was similar. In particular, the benefit of statin in group A was different compared with group D (interaction p=0.042) Conclusion: The benefit of statin in patients with MI was different according to the presence or absence of dyslipidemia. In particular, because of the insufficient benefit of statin in patients with MI and dyslipidemia, a different lipid-lowering strategy is necessary in these patients.

AB - Background and Objectives: The differential benefit of statin according to the state of dyslipidemia has been sparsely investigated. We sought to address the efficacy of statin in secondary prevention of myocardial infarction (MI) according to the level of triglyceride and high density lipoprotein cholesterol (HDL-C) on admission. Subjects and Methods: Acute MI patients (24653) were enrolled and the total patients were divided according to level of triglyceride and HDL-C on admission: group A (HDL-C≥40 mg/dL and triglyceride<150 mg/dL; n=11819), group B (HDL-C≥40 mg/dL and triglyceride≥150 mg/dL; n=3329), group C (HDL-C<40 mg/dL and triglyceride<150 mg/dL; n=6062), and group D (HDL-C<40 mg/dL & triglyceride≥150 mg/dL; n=3443). We evaluated the differential efficacy of statin according to the presence or absence of component of dyslipidemia. The primary end points were major adverse cardiac events (MACE) for 2 years. Results: Statin therapy significantly reduced the risk of MACE in group A (hazard ratio =0.676; 95% confidence interval: 0.582-0.785; p<0.001). However, the efficacy of statin was not prominent in groups B, C, or D. In a propensity-matched population, the result was similar. In particular, the benefit of statin in group A was different compared with group D (interaction p=0.042) Conclusion: The benefit of statin in patients with MI was different according to the presence or absence of dyslipidemia. In particular, because of the insufficient benefit of statin in patients with MI and dyslipidemia, a different lipid-lowering strategy is necessary in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84979655998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979655998&partnerID=8YFLogxK

U2 - 10.4070/kcj.2016.46.3.324

DO - 10.4070/kcj.2016.46.3.324

M3 - Article

AN - SCOPUS:84979655998

VL - 46

SP - 324

EP - 334

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 3

ER -